ArticleHaematologica2026
Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party.Bone marrow transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (alloHSCT) from mismatched unrelated donors (MMUD) carries high risks of non-relapse mortality (NRM) and graft-versus-host disease (GvHD). Post-transplant cyclophosphamide (PTCY) has emerged as an alternative to antithymocyte globulin (ATG) for GvHD prophylaxis. This single-center retrospective study compared PTCY (N=41) to high-dose ATG and low-dose ATG in 155 MMUD alloHSCT recipients. PTCY was associated with better overall survival with a 1-year overall survival of 78.7% versus 56.5% in the PTCY and high-dose ATG groups (P=0.007) and 64.8% in the low-dose ATG group (P=0.059), driven by a significant reduction in NRM (P=0.008), with a 1-year NRM in the PTCY group of 7.7% versus 24.4% in the high-dose ATG group (P=0.031) and 29.8% in the low-dose group (P=0.026). The relapse incidence was similar between the groups (17.5% vs. 25.7% and 16.2% for the PTCY, high-dose ATG and low-dose ATG groups, respectively; P=0.830), despite a better progression-free survival in the PTCY group (P=0.034) with 1-year progression-free survival being 78.4% compared with 50.0% in the high-dose ATG group (P=0.002) and 54.0% in the low-dose group (P=0.041). Day-100 grade II-IV and grade III-IV acute GvHD, as well as 1-year chronic GvHD and moderate/severe chronic GvHD were not significantly different. However, 1-year GvHD-related mortality was lower in the PTCY group (2.6% vs. 14.4% and 14.9% in the high- and low-dose ATG groups, respectively; P=0.018). Infection-related mortality was similar across groups, but cytomegalovirus and Epstein-Barr virus infections were less frequent with PTCY, a finding potentially linked to differences in immune reconstitution. Compared to high-dose and low-dose ATG, PTCY prophylaxis was associated with improved overall survival and progression-free survival as well as lower NRM in MMUD alloHSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.